Thomas Vanwolleghem

5.7k total citations · 1 hit paper
84 papers, 2.5k citations indexed

About

Thomas Vanwolleghem is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Thomas Vanwolleghem has authored 84 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Hepatology, 60 papers in Epidemiology and 11 papers in Infectious Diseases. Recurrent topics in Thomas Vanwolleghem's work include Hepatitis C virus research (46 papers), Hepatitis B Virus Studies (44 papers) and Liver Disease Diagnosis and Treatment (39 papers). Thomas Vanwolleghem is often cited by papers focused on Hepatitis C virus research (46 papers), Hepatitis B Virus Studies (44 papers) and Liver Disease Diagnosis and Treatment (39 papers). Thomas Vanwolleghem collaborates with scholars based in Belgium, Netherlands and United States. Thomas Vanwolleghem's co-authors include Geert Leroux‐Roels, Philip Meuleman, André Boonstra, Isabelle Desombere, Mamadou Dramé, Frédéric Clément, Jeanne‐Marie Devaster, Isabel Leroux‐Roels, Astrid Borkowski and Harry L.A. Janssen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Gastroenterology.

In The Last Decade

Thomas Vanwolleghem

74 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro

2006 331 citations Brett D. Lindenbach, Philip Meuleman et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Thomas Vanwolleghem

Since Specialization

Citations

This map shows the geographic impact of Thomas Vanwolleghem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Vanwolleghem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Vanwolleghem more than expected).

Fields of papers citing papers by Thomas Vanwolleghem

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Vanwolleghem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Vanwolleghem. The network helps show where Thomas Vanwolleghem may publish in the future.

Co-authorship network of co-authors of Thomas Vanwolleghem

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Vanwolleghem. A scholar is included among the top collaborators of Thomas Vanwolleghem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Vanwolleghem. Thomas Vanwolleghem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis B. 2025 ·PubMed ·Florian van Bömmel, Thierry Verbinnen, Kosh Agarwal, Thomas Vanwolleghem, Pietro Lampertico, (unknown), Ewa Janczewska, Marc Bourlière, (unknown), Kathleen Donohue, (unknown), Thomas N. Kakuda, Sandra De Meyer, (unknown), Michael Biermer, Oliver Lenz	0
2	Long‐term outcome of hepatitis delta in different regions world‐wide: Results of the Hepatitis Delta International Network 2024 ·Liver International ·Anika Wranke, (unknown), (unknown), George Ν. Dalekos, Mario Rizzetto, (unknown), Grazia Anna Niro, Onur Keskın, (unknown), (unknown), Patrick Ingiliz, Marion Muche, Marı́a Buti, Mathias Jachs, Thomas Vanwolleghem, Markus Cornberg, Zaigham Abbas, Cihan Yurdaydın, (unknown), Heiner Wedemeyer, (unknown)	4
3	JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2 2024 ·Journal of Hepatology ·Kosh Agarwal, Marı́a Buti, Florian van Bömmel, Pietro Lampertico, Ewa Janczewska, Marc Bourlière, Thomas Vanwolleghem, Oliver Lenz, Thierry Verbinnen, Thomas N. Kakuda, Cristiana Mayer, (unknown), Daniel G. Muenz, Maria Beumont, Ronald Kalmeijer, Michael Biermer, Isabelle Lonjon‐Domanec	22
4	Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy 2024 ·JHEP Reports ·(unknown), Maaike Biewenga, Joost P.H. Drenth, Xavier Verhelst, (unknown), Ynto S. de Boer, Gerd Bouma, (unknown), Robert C. Verdonk, (unknown), Johannes T. Brouwer, Thomas Vanwolleghem, Willem J. Lammers, Ulrich Beuers, Arantza Fariña Sarasqueta, Joanne Verheij, Tania Roskams, (unknown), Maarten E. Tushuizen, Bart van Hoek, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	6
5	Progression of the FIB-4 index among patients with chronic HCV infection and early liver disease 2023 ·BMJ Open Gastroenterology ·(unknown), Raoel Maan, Amy Puenpatom, Nicole S. Erler, Christoph Welsch, Stijn Van Hees, (unknown), Johannes Vermehren, Robert J. de Knegt, Bettina E. Hansen, Stefan Zeuzem, Thomas Vanwolleghem, Harry L.A. Janssen, Robert A. de Man, Jordan J. Feld, Rozanne C. de Veer	1
6	Ascites is the most frequent decompensating event in stable And strictly compensated NAFLD with advanced fibrosis 2023 ·Journal of Hepatology ·(unknown), Luisa Vonghia, (unknown), (unknown), Thomas Vanwolleghem, Sven Francque, Wilhelmus J. Kwanten	0
7	Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis 2023 ·Journal of Autoimmunity ·Benedetta Terziroli Beretta‐Piccoli, Gustav Buescher, George Ν. Dalekos, Kalliopi Zachou, Anja Geerts, Nasser Semmo, (unknown), Eléonora De Martin, Maciej K. Janik, (unknown), (unknown), Jérôme Dumortier, Thomas Vanwolleghem, (unknown), (unknown), Florence Lacaille, Marcial Sebode	6
8	Nivolumab and anti-HCV activity, a case report 2020 ·Acta Clinica Belgica ·(unknown), Annelies Janssens, Luisa Vonghia, P. Michielsen, Jo Raskin, Ann Driessen, Stijn Van Hees, Sven Francque, Thomas Vanwolleghem	3
9	Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV 2020 ·Journal of Hepatology ·Thomas Vanwolleghem, Zwier M. A. Groothuismink, Kim Kreefft, Magdeleine Hung, Nikolai Novikov, André Boonstra	43
10	Point-of-Care Tests for Hepatitis B Are Associated with A Higher Linkage to Care and Lower Cost Compared to Venepuncture Sampling During Outreach Screenings in an Asian Migrant Population 2020 ·Annals of Global Health ·Erwin Ho, P. Michielsen, Pierre Van Damme, Margareta Ieven, Irene Veldhuijzen, Thomas Vanwolleghem	14
11	Sustained off‐treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue–induced HBeAg seroconversion 2019 ·Journal of Viral Hepatitis ·Stijn Van Hees, Heng Chi, Bettina E. Hansen, Stefan Bourgeois, Hans Van Vlierberghe, Thomas Sersté, Sven Francque, David Wong, D. Sprengers, Christophe Moreno, Frederik Nevens, Harry L.A. Janssen, Thomas Vanwolleghem	5
12	Biobanking for Viral Hepatitis Research 2019 ·Frontiers in Medicine ·Erwin Ho, Stijn Van Hees, Sofie Goethals, Elke Smits, Manon Huizing, Sven Francque, Benedicte Y. De Winter, P. Michielsen, Thomas Vanwolleghem	7
13	Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up 2019 ·BMC Public Health ·(unknown), Vanessa Suin, Chloé Wyndham-Thomas, Sophie Quoilin, Gaëtan Muyldermans, Thomas Vanwolleghem, Benoît Kabamba‐Mukadi, (unknown), (unknown), Steven Van Gucht, Veronik Hutse	16
14	Dosing Tenofovir Disoproxil Fumarate during Different Modalities of Renal Replacement Therapy: A Pharmacokinetic Study 2018 ·Journal of Antivirals & Antiretrovirals ·Karolien Dams, Philippe G. Jorens, Jonas Weyler, Sven Francque, Thomas Vanwolleghem, David M. Burger	0
15	Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation 2017 ·Clinical Infectious Diseases ·Heng Chi, David Wong, Jie Peng, Jiawei Cao, Stijn Van Hees, Thomas Vanwolleghem, Xun Qi, Liang Chen, Jordan J. Feld, Robert J. de Knegt, Bettina E. Hansen, Harry L.A. Janssen	26
16	Belgian experience with direct acting antivirals in people who inject drugs 2017 ·Drug and Alcohol Dependence ·Rob Bielen, Christophe Moreno, Hans Van Vlierberghe, Stefan Bourgeois, (unknown), Thomas Vanwolleghem, Wim Verlinden, (unknown), Jochen Decaestecker, Chantal de Galocsy, (unknown), Mike Cool, (unknown), Christophe Van Steenkiste, F D’Heygere, Wilfried Cools, Frederik Nevens, Geert Robaeys	19
17	Liver Fibrosis Evaluation Using Real‐time Shear Wave Elastography in Hepatitis C–Monoinfected and Human Immunodeficiency Virus/Hepatitis C–Coinfected Patients 2016 ·Journal of Ultrasound in Medicine ·Wim Verlinden, Stefan Bourgeois, (unknown), (unknown), Luisa Vonghia, Thomas Vanwolleghem, P. Michielsen, Sven Francque	15
18	Reversible severe hepatitis in anorexia nervosa 2014 ·European Journal of Gastroenterology & Hepatology ·Dewkoemar Ramsoekh, Pavel Taimr, Thomas Vanwolleghem	14
19	Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver–chimeric mice from infection with a homologous hepatitis C virus strain 2008 ·Hepatology ·Thomas Vanwolleghem, Jens Bukh, Philip Meuleman, Isabelle Desombere, Jean‐Christophe Meunier, Harvey J. Alter, Robert H. Purcell, Geert Leroux‐Roels	117
20	Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro breakdown → 2006 ·Proceedings of the National Academy of Sciences ·Brett D. Lindenbach, Philip Meuleman, Alexander Ploß, Thomas Vanwolleghem, Andrew J. Syder, Jane A. McKeating, Robert E. Lanford, Stephen M. Feinstone, Marian Major, Geert Leroux‐Roels, Charles M. Rice	331

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact